Related Experiment Video

Updated: May 21, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Percutaneous Coronary Intervention for Heart Failure due to Coronary Artery Disease

Arushi Singh1, Robert S Zhang1, Sripal Bangalore1

  • 1Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY 10016, USA.

Heart Failure Clinics
|March 19, 2025
PubMed

Insights

Percutaneous coronary intervention (PCI) may improve quality of life in heart failure patients but does not clearly reduce mortality or cardiovascular events. Further research is needed to identify specific patient groups who benefit from PCI.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Heart Failure Management

Background:

  • Revascularization, including percutaneous coronary intervention (PCI), is established for acute coronary syndromes.
  • The benefit of revascularization beyond guideline-directed medical therapy (GDMT) in heart failure (HF) remains debated.
  • PCI is recognized for improving angina and quality of life in chronic coronary disease and HF.

Purpose of the Study:

  • To evaluate the incremental value of revascularization with PCI in patients with heart failure.
  • To assess the impact of PCI on mortality, cardiovascular events, and ejection fraction compared to medical therapy alone.

Main Methods:

  • Review of current data and existing clinical trials regarding PCI in heart failure patients.
  • Analysis of outcomes including mortality, cardiovascular events, ejection fraction, angina, and quality of life.

Main Results:

  • Available data supports PCI for improving angina and quality of life in chronic coronary disease and heart failure.
  • Insufficient evidence exists to confirm that PCI improves mortality, reduces cardiovascular events, or enhances ejection fraction over medical therapy alone.

Conclusions:

  • PCI offers symptomatic benefits for select heart failure patients with coronary disease.
  • Further clinical trials are essential to identify heart failure patients who may benefit from revascularization.
  • Optimal revascularization strategies for heart failure populations require further investigation.

Keywords:
Coronary artery diseaseHeart failurePercutaneous coronary interventionRevascularization

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.6K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
124
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K